Ir para o conteúdo principal

Artivion (NYSE: AORT) — Perfil da empresa, notícias e dados financeiros

Logo de Artivion
AORT Artivion
Artivion primary media
Perfil da empresa

Artivion

Sobre

Explorar empresas de United States

Artivion (NYSE:AORT) specializes in medical technology focusing on a variety of surgical solutions and patient care innovations. The company is deeply involved in the research, development, and distribution of medical devices that address the needs of cardiovascular and neurological surgeries. Through its advanced products and services, Artivion aims to improve clinical outcomes for patients, enabling healthier lives and improved recovery times. A significant part of its mission is to continually invest in new technologies and projects that push the boundaries of medical science, ensuring that healthcare professionals have access to the latest advancements in medical procedures. With a commitment to excellence and innovation, Artivion strives to lead in the creation and delivery of groundbreaking care solutions that make a real difference in people’s lives.

Resumo

Public USParticipação acionária
1984Ano de fundação
1500Funcionários
Georgia, United StatesSede
Carregando mapa...
Presença global

Operações

Todos os locais
United States

Produtos e/ou serviços de Artivion

  • CryoValve SG pulmonary heart valve, a decellularized human valve designed to replace a diseased, damaged, or malfunctioning heart valve.
  • PhotoFix bovine pericardium patch, treated with glutaraldehyde for durable cardiac and vascular repairs.
  • BioGlue surgical adhesive, designed for cardiac and vascular surgical procedures, offering a unique solution for tissue adherence and sealing.
  • Aortic Stent Grafts: These are minimally invasive devices used to repair weakened or damaged sections of the aorta, the major artery that carries blood away from the heart.
  • On-X Mechanical Heart Valves: These valves are implanted to replace diseased aortic or mitral valves in the heart.
  • AMDS™ Hybrid Prosthesis: This device is a minimally invasive option for repairing aneurysms of the aortic arch, the topmost section of the aorta.

equipe executiva do Artivion

  • James Patrick MackinChairman, President & CEO
  • Lance A. BerryEVP, COO, CFO & Treasurer
  • Jean F. HollowaySenior VP, General Counsel, Chief Compliance Officer & Corporate Secretary
  • John E. DavisSenior VP & Chief Commercial Officer
  • Amy D. HortonVP & Chief Accounting Officer
  • Matthew A. GetzVP of Human Resources & Chief Human Resources Officer
  • Jason D. AsperSenior VP and Chief Strategy & Digital Officer
  • Andrew M. GreenSenior Vice President of Regulatory & Quality
  • Simona ZannettiSenior Vice President of Clinical Research & Chief Medical Officer
  • Robert C. ThomsonVice President of Research & Development

Últimas notícias sobre a Artivion

  1. Artivion receives FDA PMA approval for AMDS Hybrid Prosthesis

    United States

  2. Artivion consolidates aortic arch portfolio with $135M Endospan acquisition

    United States

  3. Artivion announces FDA approval of NEXUS Aortic Arch System; set to acquire Endospan

    United States

Principais indicadores financeiros

Resultados divulgados pela Artivion, em USD.

Cap. de mercado
1,1 bi
Receita (TTM)
471,5 mi
P/L
—
LPA (diluído, TTM)
-0.1
Dividend yield
—
Margem de lucro
-0.7%
Receita e lucro anuais da Artivion
Fim do ano fiscalReceitaResultado operacionalLucro líquido
441,3 mi26,7 mi9,8 mi
388,5 mi38,9 mi-13,4 mi
354 mi5,7 mi-30,7 mi
313,8 mi6,2 mi-19,2 mi
Preço da ação e fundamentos de AORT